Octreotida

Presentación

Solución de liberación inmediata 50–500 mcg/mL — documentado: Sandostatin, Novartis (FDA)

¿Para qué sirve octreotida? Indicaciones autorizadas

1 INDICATIONS AND USAGE Sandostatin Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the…

Leer la sección completa

1 INDICATIONS AND USAGE Sandostatin Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 ) Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Sandostatin Injection; these trials were not optimally designed to detect such effects. ( 1.4 ) 1.1 Acromegaly Sandostatin Injection is indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. 1.2 Carcinoid Tumors Sandostatin Injection is indicated for treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. 1.3 Vasoactive Intestinal Peptide Tumors Sandostatin Injection is indicated for the treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas)-secreting tumors. 1.4 Important Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Sandostatin Injection; these trials were not optimally designed to detect such effects.

FDA (DailyMed) · Sandostatin · Indications and usage · texto original en inglés

Contraindicaciones de octreotida

4 CONTRAINDICATIONS Sensitivity to this drug or any of its components. Sensitivity to this drug or any of its components. ( 4 )

FDA (DailyMed) · Sandostatin · Contraindications · texto original en inglés

Ajuste en insuficiencia renal

Parámetro que cita la fuente: Diálisis / TRRC

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 8.6 Renal Impairment In patients with severe renal failure requiring dialysis, the half-life of Sandostatin may be increased, necessitating adjustment of the maintenance dosage [see Clinical Pharmacology (12.3)] . 8.7 Hepatic Impairment-Cirrhotic Patients In patients with liver cirrhosis, the half-life of the drug may be increased, necessitating adjustment of the maintenance dosage [see Clinical Pharmacology (12.3)] .

FDA (DailyMed) · Sandostatin · Use in specific populations · texto original en inglés

Ajuste en insuficiencia hepática

Pain with subcutaneous administration may be reduced by using the smallest volume that will deliver the desired dose.

FDA (DailyMed) · Sandostatin · Dosage and administration · texto original en inglés

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 8.6 Renal Impairment In patients with severe renal failure requiring dialysis, the half-life of Sandostatin may be increased, necessitating adjustment of the maintenance dosage [see Clinical Pharmacology (12.3)] . 8.7 Hepatic Impairment-Cirrhotic Patients In patients with liver cirrhosis, the half-life of the drug may be increased, necessitating adjustment of the maintenance dosage [see Clinical Pharmacology (12.3)] .

FDA (DailyMed) · Sandostatin · Use in specific populations · texto original en inglés

Reconstitución de octreotida

No requiere.

Dilución de octreotida

SF 0.9% o glucosa 5% (50–200 mL), infusión IV en 15–30 min, o bolo IV en 3 min.

Administración de octreotida

SC o infusión IV.

Estabilidad y periodo de validez

Compatibilidad de octreotida

Compatible con

• SF 0.9%
• Glucosa 5%

Conservación y protección de la luz

Refrigerar entre 2 y 8 °C.

Proteger de la luz; a temperatura ambiente solo es estable 14 días si está protegida de la luz.

Advertencias

• Puede alterar la glucemia (hipo- o hiperglucemia): ajustar insulina.
• Abrir las ampolletas justo antes de usarlas.

Diferencias entre fuentes oficiales

• La búsqueda en AEMPS devolvió Sandostatin LAR (formulación de liberación prolongada, IM mensual), que es otro producto y no se usó.

Fuentes

1. FDA (DailyMed) · SandostatinNovartis Pharmaceuticals Corporation · Sandostatin ampollas 50, 100 y 500 mcg/mL (liberación inmediata) · versión 2026-07-22

Interacciones de octreotida

3 medicamentos del catálogo con una interacción documentada en sus fichas oficiales. Abre cada una para ver el efecto, la recomendación y su fuente.

• CiclosporinaModerada
• Insulina glarginaModerada
• Insulina humana regularModerada

Identificación

SNOMED CT (VTM)

126155003

RxNorm

7617